Status:
UNKNOWN
Selective Serotonin Reuptake Inhibitors, Fluoxetine Versus the Standard Oral Desmopressin for Management of Mono-symptomatic Nocturnal Enuresis.
Lead Sponsor:
Fayoum University Hospital
Conditions:
Nocturnal Enuresis
Enuresis
Eligibility:
All Genders
8-16 years
Phase:
NA
Brief Summary
To determine whether there is a role for the selective serotonin reuptake inhibitors fluoxetine versus desmopressin in the treatment of nocturnal enuresis in children who have not responded to standar...
Eligibility Criteria
Inclusion
- Age ≥ 7 years
- Severe enuresis with at least (50%) seven wet nights out of 14
- Failed treatment
- The enuresis alarm was either ineffective or considered impractical due to the family circumstances.
Exclusion
- Underlying renal, urologic, neurologic, endocrinologic, or cardiac conditions
- Patients with psychiatric disorders and behavioral disorders including depression, attention-deficit/hyperactivity disorder.
- Untreated constipation
- Contraindications to fluoxetine or desmopressin treatment
Key Trial Info
Start Date :
December 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06185361
Start Date
December 1 2022
End Date
March 1 2024
Last Update
December 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of medicine, Fayoum University
Al Fayyum, Egypt, 63514